Physician profile
Joseph Fuller
NPI 1376559351
$3,124.98
in general payments reported to CMS, 2019-2025
20 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2021: $432 · 2022: $412 · 2023: $326 · 2024: $262 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $895.86 | 2021-2025 | Airsupra, Breztri |
| Axsome Therapeutics, INC. | $481.86 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.58 | 2019-2022 | |
| Alkermes, INC. | $194.69 | 2021-2025 | Aristada, Aristada Initio, Vivitrol |
| Abbvie INC. | $168.56 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $130.24 | 2025 | |
| Lilly USA, LLC | $128.86 | 2021-2023 | Jardiance |
| Amgen INC. | $122.16 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.57 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $115.65 | 2022 | |
| Gilead Sciences, INC. | $105.09 | 2022-2023 | |
| Sanofi Pasteur INC. | $94.99 | 2019 | |
| Baxter Healthcare | $61.48 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Esperion Therapeutics, INC. | $52.14 | 2021 | |
| Boston Scientific Corporation | $42.15 | 2023-2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $38.80 | 2024 | Fanapt |
| Pfizer INC. | $37.29 | 2019 | |
| Novo Nordisk INC | $25.38 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.68 | 2023 | Trintellix |
| Dynavax Technologies Corporation | $14.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Fuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.